

Preventing Influenza A Virus Infection by Mixed Inhibition of Neuraminidase and Hemagglutinin by Divalent Inhibitors

Xuan Wei, Wenjuan Du, Margherita Duca, Guangyun Yu, Erik de Vries, Cornelis A. M. de Haan,* and Roland J. Pieters*

Cite This: *J. Med. Chem.* 2022, 65, 7312–7323

Read Online

ACCESS |



Metrics & More




Article Recommendations



Supporting Information

ABSTRACT: Divalent inhibitors of the neuraminidase enzyme (NA) of the Influenza A virus were synthesized with vastly different spacers. The spacers varied from 14 to 56 atoms and were relatively rigid by way of the building blocks and their connection by CuAAC. As the ligand for these constructs, a $\Delta^4\beta$ -D-glucoronide was used, which can be prepared from *N*-acetyl glucosamine. This ligand showed good NA inhibitory potency but with room for improvement by multivalency enhancement. The synthesized compounds showed modest potency enhancement in NA activity assays but a sizeable potency increase in a 4-day cytopathic effect assay. The demonstration that the compounds can also inhibit hemagglutinin in addition to NA may be the cause of the enhancement.



INTRODUCTION

The Influenza A virus (IAV) is a notable cause of flu. The disease can take on deadly forms as exemplified by the so-called Spanish flu in 1918 with millions of victims,¹ while IAVs continuously pose a serious threat for future pandemics.² Of the two envelop proteins, hemagglutinin (HA) is responsible for viral attachment to cells by sialoglycan binding, while neuraminidase (NA) cleaves off sialic acids from sialoglycan receptors, thereby enabling the release of virions from (decoy) receptors and virion mobility.^{3,4} A balance between HA and NA has been identified as important for viral virulence.^{3,5,6} The main prophylactic intervention against an IAV infection is the use of vaccines. Antigenic variation of seasonal IAVs is a challenge, however, this requires frequent vaccine updates and may cause mismatches with viruses in the field.⁷ NA inhibitors (NAIs) have shown their value as therapeutic intervention. Potent NAIs such as oseltamivir or zanamivir are applied to reduce the illness symptoms and infectivity.⁸ However, resistance to the NAIs⁹ greatly hampers the effectiveness of the therapy.

Difluorosialic acids have shown promise against NAI-resistant NAs,¹⁰ but this is also true for multivalent NAIs.¹¹ Multivalent NAIs also showed intriguing features besides activity against resistant NAs, such as activity at much lower concentrations than zanamivir itself. Furthermore, divalent zanamivir stays in tissues much longer than monovalent.¹² None of these aspects are currently well understood.


Considering the tetrameric composition of NA proteins and the presence of ca. 40–50 copies of them on a single virion,¹³ an enhancing effect of multivalent ligands does not seem surprising. In early studies, attaching a spacer to the 7-hydroxyl

of zanamivir was introduced as the preferred method to maintain inhibitory activity.¹⁴ Linking zanamivir to flexible spacers or spacers of various lengths showed that there was a clear preference for a 16 atom spacer. Both longer and shorter spacers were less effective. Considering that the distance between the four catalytic sites within an NA tetramer is typically between 40 and 50 Å, the short dimers are not bridging between catalytic sites but bridging between tetramers or even between NAs on different virions. The most striking effects were a 2000-fold enhanced infection inhibition and a ca. 100-fold enhanced lung retention of the divalent inhibitors.¹⁵ The results were confirmed in related studies and even in animal studies,^{16–20} but interestingly, no multivalency effects were observed in the inhibition of the NA enzymatic activity by a monovalent MUNANA (4-methylumbelliferyl *N*-acetyl- α -D-neuraminic acid) probe. An exception was a study involving higher valent versions of difluorinated zanamivir, where a 145-fold enhanced NA inhibition was observed.²¹ An interesting study reported tetravalent zanamivir with different lengths of the flexible poly(ethylene glycol) (PEG) spacer arms.¹¹ No enhancement was observed in the MUNANA assay with N2 and N9, but a 6-fold enhancement per ligand with a resistant variant of N2 was observed. A surface plasmon resonance assay revealed a 60-fold and 1400-fold binding enhancement for NA

Received: February 27, 2022

Published: May 12, 2022



Scheme 1. Synthesis of Monovalent 2NA Inhibitors^a

^aReagents and conditions: (a) Troc-Cl, NaHCO₃, H₂O, 14 h (98%); (b) Ac₂O, py (95%); (c) HBr, AcOH, CH₂Cl₂ (95%); (d) AgOTf, CH₂Cl₂, −78 °C (65%); (e) AgOTf, CH₂Cl₂, r.t. (75%); (f) Zn, Ac₂O (75%); (g) NaOMe, MeOH (99%); (h) (i) TEMPO, PhI(OAc)₂, CH₂Cl₂, ^tBuOH, H₂O, AcOH, 14 h; (ii) MeI, K₂CO₃, DMF; (iii) Ac₂O, DMAP (46%); (j) DBU, CH₂Cl₂, 24 h (76%); (k) NaOH, MeOH, H₂O, 0 °C, 14 h (96%).

and a resistant variant, respectively. The fact that no major effects were seen in a cytopathic effect (CPE) assay, whereas an *in vivo* assay showed full protection, makes this system hard to comprehend. The combination of all mentioned results paints an intriguing picture with strong and useful effects of short dimers presumably by bridging between tetramers or whole viruses, while the major binding enhancements for large tetramers show likely chelation within a tetramer. A compound that combines these effects may be even more potent and could be a long-lasting chelator that could act in synergy with related HA inhibitors, such as those we recently reported.²²

Here, we report on a series of divalent NAIs with vastly different spacer lengths. The spacers used are rigidified with equatorially linked 1,4-glucose moieties, triazoles, and 1,4-substituted phenyl groups. These building blocks were previously successfully applied in divalent galactose inhibitors of the *Pseudomonas aeruginosa* lectin LecA.²³ Instead of using zanamivir, we used an oseltamivir carboxylate mimic (OCM, Scheme 1), a Δ^4 - β -D-glucuronide, as the monovalent starting point.²⁴ This compound binds strongly to NA proteins but not as strong as oseltamivir carboxylate (OC, Scheme 1), the hydrolyzed version of the prodrug oseltamivir, although a direct comparison was not made. The weaker binding allows multivalency enhancements to be more easily determined, without entering sub-nano-molar potencies. A nice feature of OCM is that it can be synthesized from cheap glucosamine. By looking at NA X-ray structures,²⁵ attaching a spacer to the 3-pentanol unit of OCM would not disrupt the binding. To this end, compound 12 and its diastereomer 13 were designed, synthesized, linked to four different spacers, and evaluated. One of the dimers was shown to inhibit infection much better than OCM and even better than OC by enhanced NA binding but surprisingly also by HA binding.

RESULTS

The proposed ligand 12 was synthesized as shown in Scheme 1. First, donor 4 was synthesized in three steps. The 2,2,2-trichloroethoxycarbonyl (Troc) group was selected to enhance the glycosylation reaction. Using, the enantio-pure alcohol S-5, we found that glycosylation yielded either β -isomer 6 or the α -

isomer, depending on the temperature of the reaction. At −78 °C, it was possible to isolate the desired β -isomer 6 in 65% yield, which was converted to 8, in which the Troc group was replaced with an acetyl group. Deprotecting the hydroxyl groups under Zemplén conditions yielded 9. Next, a three-step procedure of C(6) oxidation, ester formation by MeI, and alcohol acetylation yielded 10. 1,8-Diazabicyclo(5.4.0)undec-7-ene (DBU)-mediated β -elimination gave 11, and after ester hydrolysis, 12 was obtained. Using the same procedures, the other stereoisomers 13–15 were prepared and characterized. Compound 13 was prepared by using *rac*-5 instead of S-5 in the glycosylation, followed by diastereomer separation at the stage of compound 8. Performing the remaining steps led to 13. Similarly, using *rac*-5 in the glycosylation of 4 under α -isomer-producing conditions at room temperature, a diastereomeric mixture of 7a and 7b was obtained, presumably yielding the more thermodynamically stable product, which was subsequently converted to separate isomers 14 and 15, whose stereochemistry of the tail was not deciphered.

Recombinant soluble N9 protein (N9 Spain) stabilized as a tetramer using a tetrabrachion oligomerization domain²⁶ was used to assess the ability of the compounds (12–15) as well as the parent structure OCM to inhibit NA activity using the MUNANA substrate. The activity in the absence of inhibitory compounds was set at 100% (Figure 1). Clearly, β -compounds 12 and 13 displayed much more inhibitory activity than α -compounds 14 and 15, with 12 being the most active compound, besides the control parent OCM. Extension of the original pentanol tail results in some reduction of potency, 6-fold in this case. Nevertheless, 12 retained enough inhibitory potency; thus, it was selected for conjugation to spacers to induce multivalency effects.

In order to get an idea about the distances that spacer systems would need to cover, docking studies were performed. Using a zanamivir complex of a representative N1 [derived from A/California/07/2009 (H1N1) pdb 4BQ7],²⁷ a series of conformations of OCM were allowed to dock to the entire NA tetramer using the hybrid docking mode of the OpenEye software suite. The lowest energy binding poses include OCM ligands bound to all four sites in a binding mode similar to that




Figure 1. Results of the NA (N9 Spain) MUNANA enzyme inhibition assay using several ligands: orange = OCM (IC_{50} $0.47 \pm 0.1 \mu M$); green = 12 (IC_{50} $2.9 \pm 0.7 \mu M$); purple = 13 (IC_{50} $28.2 \pm 2 \mu M$); red and blue = 14 and 15, no inhibition.

of zanamivir (Figure S3) and spaced over ca. 47 Å (Figure 2), measured between the 3-pentanol tails.




Figure 2. Complex obtained from docking studies, with the lowest energy bound OCM ligands of each of the four binding sites using the N1 of A/California/07/2009 (H1N1) (PDB 4BQ7);²⁷ the distances measured along the black lines between the terminal carbons of the 3-pentanol parts are ca. 47 Å.

Based on the above, 12 was selected as the monovalent ligand to be conjugated to divalent scaffold molecules. To cover the distance between bound OCM molecules of ca. 47 Å, four conjugates 17, 19, 21, and 24 were synthesized (Scheme 2). The number of atoms between the terminal carbons of the 3-pentanol parts is 14, 28, 42, and 56 atoms, respectively. Considering that as a crude estimation a rigid spacer may be as long in angstrom as it contains atoms,²⁸ this range should see some selectivity if a chelation mechanism should play a role.

The shortest spaced compound 17a was assembled from diazido-glucoside 16²⁸ and 12 by CuAAC conjugation. Deprotection of the central glucose unit yielded 17b. Bis-azide 18²³ was also linked to 12 and yielded the longer divalent 19. Similarly, the extended bis-azide 20 was coupled to 12 to yield divalent 21. To make the longest divalent ligand of the series, a different strategy was applied. First, bis-azide 18 was monofunctionalized with 12 to yield mono-azide 22. Subsequently, 22 was coupled to bisalkyne 23 to yield the divalent 24 with the longest spacer. The synthesis of bisazido 20 is described in Scheme 3. 1-Azido galactose was converted


to 26 by *tert*-butyldimethylsilyl (TBDMS) of the primary alcohol, followed by selective benzylation of the equatorial hydroxyls. Mono-CuAAC conjugation with 1,4-diethynylbenzene yielded 27. CuAAC conjugation with bis-azide 28²⁸ yielded the symmetric 29. Introduction of azide groups, followed by sugar deprotection, yielded bis-azido spacer 20.

Compounds were first tested for their ability to inhibit NA activity using recombinant soluble tetrameric N1 and N9 proteins^{26,29} and the MUNANA substrate. As the two proteins gave similar results (Figure S2), in line with other mentioned reported systems with multivalent zanamivir units, IC_{50} values were determined for the two data sets combined (Table 1). It was clear that OC was a ca. 600-fold more potent inhibitor than our monovalent 12 with these recombinant NA enzymes, while it was ca. 100-fold more potent than inhibitor 21. Next, we analyzed the inhibitory activity of the different compounds on virus particles rather than recombinant NA proteins as the source of NA activity (Table 1 and Figure 3). While the IC_{50} values of all compounds were reduced in this assay, this was particularly the case for divalent 19 and 21, with multivalency enhancements of 20–30-fold in comparison with monovalent 12. As a result, OC was only ca. 25-fold more potent than compounds 19 and 21, while the potency difference between monovalent 12 and OC remained ca. 600-fold.

To assess the ability of the compounds to inhibit virus infection, a 4-day CPE assay was set up. MDCK cells in a 96-well format were infected with 50 TCID₅₀ units of the H1N1 virus in the presence of a dilution range of the different compounds, and the lowest concentration of the compounds that could prevent cytopathogenic effects and killing of the cells resulting from virus replication was determined. Strikingly, compounds 19, 21, and 24 displayed comparable effectivity to OC in the CPE assay. The amount of OC needed to prevent cell killing was ca. 250-fold higher than the IC_{50} value as determined using the MUNANA assay with the whole virus, while the difference was much smaller for compounds 19, 21, and 24 (33-, 4-, and 0.2-fold, respectively).

These results suggested that compounds 21 and 24 might have some additional activity, unlike OC, that contributes to the inhibition of virus replication. Therefore, we analyzed the ability of the different compounds to interfere with virus-receptor binding, a measure of HA inhibition. This was done using biolayer interferometry (BLI) as previously reported as a method that shows distinct activity of a viral HA protein and also its inhibition.^{22,30} OC, which does not interfere with HA-receptor binding, was present to completely inhibit NA activity.³ All compounds tested were able to inhibit virus-receptor binding with 21 having the largest effect at 10 μM (Figures 4 and S3). At this concentration, compounds 19 and 24 did not have increased inhibitory activity compared to monovalent 12.

To further explore the dual role of both HA and NA inhibition, the BLI experiment was modified. The inhibitory potency of the most potent compound 21 was studied in the presence and absence of OC. In the presence of OC alone, virus binding is observed (Figure 5a), similar to the previous experiment. In agreement with the previous experiment, 21 inhibited virus-receptor binding in the presence of OC. In the absence of any inhibitory compounds including OC, a low level of virus binding is observed, which decreased with time, resulting from the virus being released from the sensor surface in an NA-dependent manner. Interestingly, the presence of 21 alone is sufficient to prevent apparent viral binding to the

Scheme 2. Synthesis of Divalent Inhibitors^a

^aReagents and conditions: (a) **12** (2 equiv) CuSO₄·5H₂O, sodium ascorbate, ^tBuOH, H₂O, 10 h, 63% (**17a**), 52% (**19**), 41% (**21**); (b) **12** (1 equiv) CuSO₄·5H₂O, sodium ascorbate, ^tBuOH, H₂O, 10 h, 45%; (c) CuSO₄·5H₂O, sodium ascorbate, ^tBuOH, H₂O, 10 h, 28%.


sensor, even more so than when **OC** is additionally present, suggesting that inhibition of HA-receptor binding is stronger when binding of **21** to NA is not in competition with **OC**. To confirm whether NA activity was also affected in this experimental setup, sensors were regenerated, thereby removing all but the biotinylated glycoprotein receptor. NA activity of viruses bound in the first round was then monitored by a new virus binding experiment, this time in the presence of **OC** (Figure 5b). When sensors had been subjected to virus binding in the first round in the absence of NAIs, virus binding in the second round was reduced as a consequence of the reduction of sialoglycan receptors in the first round by NA activity. The sensor regenerated after the action of **21** (Figure 5a) is completely capable of full virus binding, indicating that **21** was able to inhibit the NA in that previous experiment. Collectively, these data confirm that **21** in contrast to **OC** inhibits not only NA activity but also HA-receptor binding.

DISCUSSION AND CONCLUSIONS

We successfully synthesized a series of derivatives of **OCM**, extended for the first time from their 5-pentanol tail, a structural feature of importance in **OC**. Of the four diastereomers tested, exclusively the β -isomers were able to inhibit NA, with a small preference for the *S*-configuration of the newly created stereocenter, that is, compound **12**. The next step was to make the compound divalent. A multivalent NAI based on **OC** has previously been reported, but the **OC** moiety was linked through its carboxylate and effects were modest in NA inhibition, likely due to the fact that the carboxylate plays a role in binding to NA.³¹ Conjugation of **12** to a series of four spacers with vastly different lengths but similar chemical features and rigidities also proved possible. The motif of alternating glucose, triazole, and occasional benzene rings was previously shown to lead to greatly enhanced divalent binding

versus a flexible PEG structure.²⁸ The spacer remains mostly linear, especially for the shorter cases, as indicated by modeling²⁸ and from X-ray structures.³² In the present study, the divalent conjugates of **12** showed inhibition in the MUNANA assay by both free NA protein tetramers or by the whole virus. The latter is more strongly inhibited by compounds **19** and **21**. The difference between the recombinant NA and full virus assay may be explained by the different experimental conditions as the compounds may be able to interact with multiple NA tetramers on virus particles or even with HA proteins on different virions. More striking results came from the MDCK CPE assay. We were able to turn a monovalent NA ligand that is a ca. 770-fold weaker NAI than **OC** into a ca. 2-fold better CPE inhibitor than **OC** by making it divalent with a specific rigid spacer (compound **21**). The MUNANA assays indicated a moderate up to 30-fold enhancement of a divalent **OCM** ligand versus its monovalent counterpart. However, a strong enhancement in the 4-day CPE assay was observed particularly for **21** and **24**, that is, the compounds with the longest spacers, relative to **OC** in comparison with the MUNANA assays. Interestingly, in the two most potent compounds, the two NA ligands are separated by 42 and 56 atoms in a relatively rigid spacer. Compound **19** with 28 atoms in the linker showed high efficacy in the MUNANA assay but somewhat less so in the infection assay. Previous work with flexible spacers showed that 16 atoms was optimal.¹⁵ Our shortest compounds **17** and **17a** with 14 atoms in the spacer were clearly not optimal.

Looking for answers, HA inhibition was studied by BLI, which revealed significant HA binding by monovalent **12** and its bivalent derivatives, with **21** being the most effective. While this type of binding was not anticipated, it should not be too surprising. Compound **12** has features in common with sialic acid. Interestingly, the inhibition of HA by **OCM** (10 μ M) can

Scheme 3. Synthesis of New Bis-azide **20**^a

^aReagents and conditions: (a) (i) TBDMSCl, pyridine; (ii) BzCl, pyridine, 0 °C, 63%; (b) CuSO₄·5H₂O, Na ascorbate, DMF/H₂O 9/1, MW 80 °C, 50 min, 60%; (c) CuSO₄·5H₂O, Na ascorbate, DMF/H₂O 9/1, MW 80 °C, 1 h, 65%; (d) (i) Tf₂O, Pyridine; (ii) NaN₃, 59%; (e) (i) NaOMe, MeOH; (ii) 6 M HCl, 47%.

Table 1. Activities (μM) of Synthesized Inhibitors

inhibition of recombinant NA tetramers in enzymatic MUNANA assay (IC ₅₀ μM) ^a						
12	17a	17b	19	21	24	OC
6.4 ± 1.0	24.4 ± 17.5	5.2 ± 2.7	3.3 ± 0.7	1.3 ± 0.4	10.6 ± 1.7	0.01 ± 0.001
inhibition of NA of the whole virus in enzymatic MUNANA assay (IC ₅₀ μM) ^a						
12	17a	17b	19	21	24	OC
2.33 ± 0.005	9.4 ± 0.4	1.5 ± 0.2	0.08 ± 0.01	0.11 ± 0.004	4.7 ± 0.9	0.004 ± 0.001
CPE reduction assay on MDCK cells ^b						
12	17a	17b	19	21	24	OC
>5	>5	>5	2.6 ± 1.7	0.45 ± 0.4	0.84 ± 0.4	1.0 ± 0.4

^aEnzyme inhibition assay by fluorescence using 100 μM MUNANA substrate and N1 and N9 recombinant proteins. Compound 24 and OC were only tested on N1. ^bCPE reduction assay on MDCK cells with 50 TCID₅₀ (median tissue infectious dose) units of Neth09H1N1, showing the lowest concentration (μM) that inhibits CPE formation at 4 days post infection. No CPE/cytotoxicity was observed at the highest concentration (5 μM) analyzed.

be observed in the presence of OC (10 μM). In our previous work on HA inhibition, low micromolar inhibition was shown for a divalent ligand in which its terminal sialic acids were separated by a similar spacer as in **21**.²² Thus, the enhanced infection inhibition of **21** may be caused by both NA and HA inhibition of the same compound. Although chelation-type

binding is a major challenge when covering distances approaching 50 Å as is the case for both NA and HA, the fact that the longest spacers showed the best inhibition of infection indicates that divalent binding may be at work in our case.




Figure 3. Inhibition of NA of the whole Neth09H1N1 virus by the indicated compounds using the MUNANA assay.




Figure 4. Inhibition of virus Neth09H1N1 binding by the compounds shown (10 μ M) to immobilized LAMP1 measured by BLI, displayed as progress curves of virus binding to the BLI sensor.

It is not the first time that multivalent ligands were able to inhibit both NA and HA. S-sialosides linked to albumin showed good HA inhibition but only weak NA inhibition and were not further studied in more biological assays.³³

The principle of such dual inhibition may have potential. The present study could provide a new impetus to aim for this dual inhibition with purposely designed compounds. These could possibly take advantage of multivalency and could prove effective and yield potent anti-infective and long-lasting activity with reduced resistance.

EXPERIMENTAL SECTION

Chemistry. Unless stated otherwise, chemicals were obtained from commercial sources and were used without further purification. Compounds **1**, **2**,³⁴ **3**,³⁵ **4**,³⁶ and **5**³⁷ were synthesized following the literature procedure. Solvents were purchased from Biosolve (Valkenswaard, The Netherlands). All moisture-sensitive reactions were performed under a nitrogen atmosphere. Anhydrous tetrahydrofuran (THF) was dried over Na/benzophenone and freshly distilled prior to use. All the other solvents were dried over molecular sieves (4 Å). Thin-layer chromatography (TLC) was performed on Merck precoated Silica 60 plates. Spots were visualized by UV light, 10% H₂SO₄ in EtOH, and triphenylphosphine in THF, followed by ninhydrin. Microwave reactions were carried out in a Biotage microwave Initiator (Uppsala, Sweden). The microwave power was limited by temperature control once the desired temperature was reached. Sealed vessels of 2–5 and 10–20 mL were used. Gel filtration chromatography was performed with columns packed with Bio-gel P-2 Fine (Bio-Rad) and Bio-gel P-6 Fine (Bio-Rad) and eluted with water. Water was purified using a Milli-Q Gradient A10 Water Purification System. Lyophilization was performed on a Christ Alpha 1-2 apparatus. Analytical liquid chromatography–mass spectrometry (LC–MS) was performed on an Agilent 6560 Ion Mobility Q-TOF LC/MS using a Waters XBridge HILIC column (5 μ m, 250 \times 4.6 mm) at a flow rate of 0.6 mL/min. The used buffers were 50 mM formic acid in H₂O (buffer A, pH 4.4) and CH₃CN




Figure 5. (a) Inhibition of HA on virus particle (Neth09H1N1) binding using BLI under various conditions; (b) sensors from (a) were regenerated and washed and exposed to the new virus in the presence of OC. The line color refers to conditions in (a) for both graphs. (c) Pictorial explanation of (a,b). Results of virus binding (inhibition) assay are shown in (a), while the results of the virus rebinding assay are shown in (b).

(buffer B). Also, UV absorption was measured at 254 nm. Purification using preparative high-performance liquid chromatography (HPLC) was performed on a Shimadzu 20A HPLC system with a Waters XBridge BEH Prep Amide column (5 μ m, 250 \times 10 mm) at a flow rate of 3.0 mL/min. Runs were performed using a standard protocol: 80–30% gradient buffer B in 60 min, with the same buffers as described for the analytical LC–MS. Also, analytical HPLC runs were performed on a Shimadzu automated HPLC system with a reversed-phase column (Alltech, C₁₈, 90 M, 5 mm, 250 L, 4.6 mm, Deerfield, IL, USA) that was equipped with an evaporative light scattering detector (PL-ELS 1000, Polymer Laboratories, Amherst, MA, USA) and a UV/vis detector operating at 220 and 250 nm. Preparative HPLC runs were performed on an Applied Biosystems workstation. Elution was effected by using a linear gradient of 5% MeCN/0.1% TFA in H₂O to 5% H₂O/0.1% TFA in MeCN. ¹H NMR spectra were recorded on a 400, 500, or 600 MHz spectrometer. ¹³C analysis was recorded at 101, 125, or 151 MHz. High-resolution mass spectrometry (HRMS) analysis was performed using an Agilent 6560 Ion Mobility Q-TOF LC/MS instrument. All tested new

compounds (i.e., 17a, 17b, 19, 21, and 24) were >95% pure by HPLC.

Compound 6. Bromide 4 (10.0 g, 18.4 mmol), 4.0 g of 4 Å powdered sieves, 8-nonyl-3-ol 5 (0.85 g, 6.04 mmol, 1.1 equiv), and 100 mL of CH₂Cl₂ were added to a flask under argon and cooled to −78 °C. AgOTf (5.70 g, 22.2 mmol) was added in portions over 40 min. The reaction was allowed to proceed for 3 days at −78 °C. The reaction mixture was then quenched with iPr₃NEt (1.44 mL, 1.50 equiv), and the solution was filtered through celite after 10 min. The crude solution was washed with concentrated Na₂S₂O₃ (2 × 20 mL), with concentrated Na₂CO₃ (2 × 20 mL), and once with brine and dried over Na₂SO₄. Chromatography with EtOAc/petroleum ether (1:3) provided 6 as a white foam (7.18 g, 65%). ¹H NMR (400 MHz, CDCl₃): δ 5.31 (d, J = 10.0 Hz, 1H, NH), 5.25 (d, J = 10.1 Hz, 1H, H-4), 4.98 (dd, J = 10.0, 9.3 Hz, 1H, H-3), 4.71 (d, J = 12.0 Hz, 1H, H-1), 4.63 (d, J = 10.7 Hz, 2H, H-6), 4.19 (dd, J = 12.1, 5.4 Hz, 1H, −Troc), 4.08 (dd, J = 12.1, 2.6 Hz, 1H, −Troc), 3.65 (ddd, J = 10.0, 5.4, 2.6 Hz, 1H, H-2), 3.56 (dt, J = 10.7, 8.6 Hz, 1H, H-5), 3.48 (q, J = 5.9, 5.4 Hz, 1H, O−CH−), 2.14 (dtt, J = 6.6, 4.1, 2.0 Hz, 2H), 2.02 (s, 3H, OAc), 1.97 (d, J = 2.0 Hz, 6H, OAc), 1.94 (t, J = 2.6 Hz, 1H, −C≡CH), 1.58–1.28 (m, 8H, −CH₂−), 0.83 (t, J = 7.4 Hz, 3H, −CH₂−CH₃). ¹³C NMR (101 MHz, CDCl₃): δ 170.62, 170.60, 169.47, 153.94, 100.25, 95.38, 84.49, 82.03, 74.41, 71.98, 71.47, 69.03, 68.61, 62.34, 56.62, 32.83, 28.34, 27.44, 24.06, 20.67, 20.61, 20.60, 18.28, 9.42. HRMS m/z: calcd for C₂₄H₃₄Cl₃NaNO₁₀ [M + Na]⁺, 624.1146; found, 624.1141.

Compound 7a and 7b Mixture. Bromide 4 (10.0 g, 18.4 mmol), 4.0 g of 4 Å powdered sieves, and 8-nonyl-3-ol (*rac*-5) (0.85 g, 6.04 mmol, 1.1 equiv) were added; 100 mL of CH₂Cl₂ was added to a flask under argon at r.t., and AgOTf (5.70 g, 22.2 mmol) was added in portions over 40 min. The reaction was allowed to proceed for 6 h at 25 °C. The reaction was then quenched with iPr₃NEt (1.44 mL, 1.50 equiv), and the solution was filtered through celite after 10 min. The crude solution was washed with concentrated Na₂S₂O₃ (2 × 20 mL), concentrated Na₂CO₃ (2 × 20 mL), and 1 × brine and dried over anhydride Na₂SO₄. Chromatography with EtOAc/petroleum ether (1:3) provided Compounds 7a and 7b as a white foam (7.65 g, 69%). ¹H NMR (400 MHz, CDCl₃): δ 5.30–5.17 (m, 4H), 5.09 (td, J = 9.7, 4.7 Hz, 2H), 4.99 (t, J = 3.2 Hz, 2H), 4.82–4.63 (m, 6H, −Troc and H-5), 4.25 (td, J = 12.2, 5.1 Hz, 4H), 4.12–3.93 (m, 4H), 3.58 (dp, J = 11.6, 5.5 Hz, 2H), 2.21 (ddt, J = 9.9, 6.9, 4.2 Hz, 4H), 2.10 (s, 3H), 2.09 (s, 3H), 2.04 (s, 6H), 2.02–2.01 (d, J = 2.0 Hz, 6H, OAc), 2.00–1.95 (m, 2H, −C≡CH), 1.65–1.42 (m, 16H, −CH₂−), 0.94 (t, J = 7.5 Hz, 3H, −CH₂−CH₃), 0.89 (t, J = 7.5 Hz, 3H, −CH₂−CH₃). ¹³C NMR (101 MHz, CDCl₃): δ 170.88, 170.85, 170.55, 170.53, 169.36, 169.32, 154.05, 96.40, 95.76, 95.32, 83.99, 80.69, 79.57, 74.46, 70.98, 70.92, 68.76, 68.71, 68.29, 68.27, 67.96, 62.04, 54.15, 54.07, 33.00, 31.93, 28.19, 28.14, 26.98, 25.35, 24.49, 23.79, 20.68, 20.66, 20.63, 20.56, 18.19, 18.15, 9.87, 8.92. HRMS m/z: calcd for C₂₄H₃₄Cl₃NaNO₁₀ [M + Na]⁺, 624.115; found, 624.105.

Compound 8. Compound 6 (5 g, 8.3 mmol) was dissolved in 20 mL of Ac₂O, 3 g of zinc dust was added, and the reaction mixture was stirred overnight. TLC showed completion, and the reaction mixture was filtered through celite, concentrated, and azeotroped (2 × 50 mL) of toluene. The crude material was flash-chromatographed with EtOAc/petroleum ether (3/2), which provided compound 8 as a white foam (2.9 g, 75%).

¹H NMR (600 MHz, CDCl₃): δ 5.73 (d, J = 8.8 Hz, 1H, NH-Ac), 5.32 (dd, J = 10.7, 9.3 Hz, 1H, H-3), 5.04 (t, J = 9.7 Hz, 1H, H-4), 4.75 (d, J = 8.3 Hz, 1H, H-1), 4.22 (dd, J = 12.1, 5.3 Hz, 1H, H-6), 4.13 (dd, J = 12.1, 2.6 Hz, 1H, H-6), 3.79 (dt, J = 10.7, 8.5 Hz, 1H, H-2), 3.70 (ddd, J = 10.0, 5.3, 2.6 Hz, 1H, H-5), 3.51 (p, J = 5.9, 5.1 Hz, 1H, O−CH−), 2.28–2.14 (m, 2H, CH₂−C≡C), 2.07 (s, 3H, Ac), 2.03 (d, J = 2.7 Hz, 6H, Ac), 2.01 (t, J = 2.7 Hz, 1H, −C≡CH), 1.95 (s, 3H, N-Ac), 1.65–1.37 (m, 8H, −CH₂−), 0.88 (t, J = 7.4 Hz, 3H, −CH₂−CH₃). ¹³C NMR (151 MHz, CDCl₃): δ 170.91, 170.73, 170.14, 169.50, 100.52, 84.77, 82.22, 72.40, 71.50, 68.98, 68.64, 62.43, 55.37, 33.00, 28.31, 27.69, 24.18, 23.37, 20.74, 20.68, 18.41, 9.56. HRMS m/z: calcd for C₂₃H₃₆NO₉ [M + H]⁺, 470.2385; found, 470.2388.

Compound 9. To a solution of compound 8 (3 g, 6.4 mmol) in anhydrous MeOH (30 mL) at 0 °C under Ar was added a solution of NaOMe (1 M in MeOH, 6 mL). The reaction mixture was initially stirred for 10 min at 0 °C, then warmed to r.t. naturally, and monitored by TLC analysis. After 2 h, the reaction mixture was neutralized with Amberlite IR-120(H+) resin. The resin was filtered off and washed with MeOH (2 × 20 mL); then, the filtrate was evaporated under reduced pressure to give a light-yellow syrup. This was purified by column chromatography (DCM/MeOH = 9/1) to furnish 9 (2.17 g, 99%) as a white solid. R_f 0.2 (DCM/MeOH = 9/1). ¹H NMR (600 MHz, D₂O): δ 4.46 (d, J = 8.5 Hz, 1H, H-1), 3.80 (dd, J = 12.3, 1.6 Hz, 1H, H-6a), 3.65–3.60 (m, 1H, H-5), 3.57–3.50 (m, 2H, H-2 and H-7), 3.45–3.38 (m, 1H, H-3), 3.35–3.27 (m, 2H, H-4 and H-6b), 2.25 (t, J = 2.6 Hz, 1H, −C≡CH), 2.12 (tt, J = 6.9, 3.0 Hz, 2H, H-13), 1.94 (s, 3H, CH₃COO−), 1.59–1.14 (m, 8H, H-8, 10, 11, 12), 0.76 (t, J = 7.5 Hz, 3H, H₃C−CH₂−). ¹³C NMR (151 MHz, D₂O): δ 174.3, 100.7, 86.2, 83.4, 75.7, 74.0, 69.8, 69.2, 60.7, 55.9, 31.8, 27.9, 26.7, 23.4, 22.3, 17.5, 8.7. HRMS m/z: calcd for C₁₇H₂₉NaNO₆ [M + Na]⁺, 366.1893; found, 366.1886.

Compound 10. To an ice-cooled solution of compound 9 (0.343 g, 1 mmol, 1.0 equiv) and PhI(OAc)₂ (0.21 g, 0.65 mmol, 2.5 equiv) in a mixture of CH₂Cl₂, ^tBuOH, and H₂O (4:4:1, 10 mL) were added TEMPO (40 mg, 0.25 mmol, 1 equiv) and AcOH (3 drops). The resulting mixture was stirred vigorously overnight at 4 °C, after which TLC analysis (DCM/MeOH, 9:1 v/v) indicated complete conversion of the starting material. The reaction mixture was then quenched with sat. aq Na₂S₂O₃ (25 mL), and aq H₃PO₄ (5 mL, 1.0 M) was added. The mixture was evaporated under reduced pressure and then loaded on a C-18 column. Reverse-phase chromatography in water afforded a white solid after lyophilization. The obtained acid was dissolved in DMF (10 mL) under N₂, and K₂CO₃ (277 mg, 2 mmol, 2.0 equiv) was added to it, followed by MeI (185 μL, 3 mmol, 3.0 equiv). The reaction mixture was stirred in the dark at r.t. for 24 h. Acetic anhydride (0.6 mL, 5.1 mmol, 5 equiv) and 4-dimethylaminopyridine (DMAP) (13.4 mg, 0.11 mmol, 11%) were then added, and stirring was continued for another 12 h at r.t. Then, water was added, and the mixture was extracted with EtOAc (3 × 50 mL). The combined organic extracts were washed with H₂O (2 × 10 mL) and brine and were dried (Na₂SO₄), filtered, and concentrated under reduced pressure. The crude residue was purified by flash chromatography (EtOAc/PE 1:9 → 3:7) to give 10 (209 mg, over 3 steps, 46%) as a white fluffy solid. ¹H NMR (600 MHz, CDCl₃): δ 5.55 (d, J = 8.5 Hz, 1H, NH), 5.41 (dd, J = 10.6, 9.3 Hz, 1H, H-3), 5.18 (dd, J = 9.9, 9.3 Hz, 1H, H-4), 4.85 (d, J = 8.2 Hz, 1H, H-1), 4.03 (d, J = 10.0 Hz, 1H, H-5), 3.74 (s, 3H, −COOCH₃), 3.74 (m, 1H, H-2), 2.04 (s, 3H, −OAc), 2.02 (s, 3H, −OAc), 2.00 (t, J = 2.6 Hz, 1H, −C≡CH), 1.95 (s, 3H, −NHAc), 1.66–1.36 (m, 8H, −CH₂−), 0.88 (t, J = 7.4 Hz, 3H, H₃C−CH₂−). ¹³C NMR (151 MHz, CDCl₃): δ 170.73, 170.09, 169.49, 167.57, 100.25, 84.78, 81.96, 72.54, 71.56, 69.80, 68.63, 55.47, 52.75, 32.76, 28.31, 27.57, 24.01, 23.38, 20.73, 20.58, 18.41, 9.50. HRMS m/z: calcd for C₂₂H₃₃NaNO₉ [M + Na]⁺, 478.2053; found, 478.2045.

Compound 11. DBU (0.2 mL, 1.2 mmol, 3 equiv) was added dropwise to a solution of compound 10 (190 mg, 0.40 mmol, 1 equiv) in anhydrous DCM (15 mL) under Ar. The light-yellow solution was stirred at r.t. for 24 h, after which it was evaporated under reduced pressure. The viscous crude product was directly loaded onto a silica column and chromatographed (EtOAc/PE 6:4, 1% MeOH) to furnish unsaturated compound 11 (120 mg, 0.3 mmol, 76%) as a transparent oil. ¹H NMR (400 MHz, CDCl₃): δ 6.22 (dd, J = 4.8, 1.3 Hz, 1H, NH), 5.60 (d, J = 9.0 Hz, 1H, H-4), 5.24 (d, J = 2.5 Hz, 1H, H-1), 5.01 (dd, J = 4.8, 2.0 Hz, 1H, H-2), 4.36 (dq, J = 9.1, 2.0 Hz, 1H, H-3), 3.79 (s, 3H, −COOCH₃), 3.63 (p, J = 5.6 Hz, 1H, O−CH−), 2.17 (td, J = 6.8, 2.6 Hz, 2H, −CH₂−), 2.02 (s, 3H, −OAc), 1.94 (s, 3H, −OAc), 1.93 (t, J = 2.6 Hz, 1H, −C≡CH), 1.56–1.35 (m, 8H, −CH₂−), 0.78 (t, J = 7.4 Hz, 3H, H₃C−CH₂−). ¹³C NMR (101 MHz, CDCl₃): δ 170.13, 169.46, 162.49, 142.40, 107.63, 96.91, 84.25, 80.30, 68.48, 64.69, 52.58, 48.95, 32.33, 28.39, 27.00, 24.00, 23.12, 20.85, 18.25, 9.23. HRMS m/z: calcd for C₂₀H₃₀NO₇ [M + H]⁺, 396.2022; found, 396.2008.

Compound 12. To a solution of compound **11** (0.10 g, 0.28 mmol) in MeOH:H₂O (1:1) at 0 °C was added aq NaOH (0.5 N) until pH 13. The reaction mixture was stirred at r.t. and monitored by TLC analysis (EtOAc/MeOH/H₂O = 8/2/1). After 16 h, the reaction mixture was neutralized with Amberlite IR-120(H⁺) resin. The resin was filtered off and washed with MeOH (2 × 10 mL); then, the filtrate was evaporated under reduced pressure to give a light-yellow syrup, which was purified by column chromatography (EtOAc/MeOH/H₂O = 10/2/1) to furnish **12** after lyophilization (0.08 g, 96%) as a white solid. *R*_f 0.2 (EtOAc/MeOH/H₂O = 8/2/1). ¹H NMR (600 MHz, CD₃OD): δ 6.07 (d, *J* = 4.2 Hz, 1H, H-4), 5.14 (d, *J* = 4.1 Hz, 1H, H-1), 4.01 (t, *J* = 3.9 Hz, 1H, H-2), 3.95 (t, *J* = 4.0 Hz, 1H, H-3), 3.59 (dq, *J* = 11.6, 5.5 Hz, 1H, H-7), 2.18–2.00 (m, 3H, H-13, CH≡C–), 1.86 (s, 3H, –Ac), 1.64–1.23 (m, 8H, –CH₂–), 0.77 (t, *J* = 7.4 Hz, 3H, H₃C–CH₂–). ¹³C NMR (151 MHz, CD₃OD): δ 171.9, 164.3, 141.2, 111.3, 98.1, 83.5, 81.4, 68.3, 64.1, 52.3, 32.6, 28.4, 26.9, 23.9, 21.2, 17.6, 8.7. HRMS *m/z*: calcd for C₁₇H₂₆NO₆ [M + H]⁺, 340.1755; found, 340.1766.

Compounds 13–15. To obtain compounds **13**, **14**, and **15**, we used the same method as for compound **12**. They were obtained as follows: compound **13** (0.08 g, 96%), a light-yellow solid. ¹H NMR (600 MHz, CD₃OD): δ 6.20 (dd, *J* = 4.3, 0.9 Hz, 1H, H-4), 5.26 (dd, *J* = 4.1, 0.9 Hz, 1H, H-1), 4.13 (dt, *J* = 3.9, 0.9 Hz, 1H, H-2), 4.07 (dt, *J* = 4.0, 0.8 Hz, 1H, H-3), 3.77–3.67 (m, 1H, H-7), 2.22–2.08 (m, 3H, H-13, CH≡C–), 1.98 (s, 3H, –Ac), 1.70–1.30 (m, 8H, –CH₂–), 0.95 (t, *J* = 7.4 Hz, 3H, H₃C–). ¹³C NMR (151 MHz, CD₃OD): δ 171.9, 164.3, 141.2, 111.3, 98.1, 83.5, 81.4, 68.3, 64.1, 52.3, 32.6, 28.4, 26.9, 23.9, 21.2, 17.6, 8.7. Compounds **14** and **15**, light-yellow solids. ¹H NMR (600 MHz, Methanol-*d*₄): δ 6.08 (dd, *J* = 2.7, 1.1 Hz, 1H, H-4), 5.25 (d, *J* = 2.8 Hz, 1H, H-1), 4.38 (dd, *J* = 9.6, 2.6 Hz, 1H, H-2), 4.04 (dd, *J* = 9.6, 2.8 Hz, 1H, H-3), 3.69 (h, *J* = 4.7 Hz, 1H, H-7), 2.26–2.16 (m, 3H, H-13, CH≡C–), 2.03 (s, 3H, –Ac), 1.60–1.44 (m, 8H, –CH₂–), 0.85 (t, *J* = 7.4 Hz, 3H, H₃C–). ¹³C NMR (151 MHz, MeOD): δ 172.1, 100.9, 83.6, 81.3, 76.4, 74.6, 70.8, 68.2, 61.5, 56.5, 32.4, 28.7, 27.1, 23.8, 21.8, 17.7, 8.5; other isomer: ¹H NMR (600 MHz, CD₃OD): δ 6.08 (dd, *J* = 2.6, 1.1 Hz, 1H, H-4), 5.24 (d, *J* = 2.8 Hz, 1H, H-1), 4.38 (dd, *J* = 9.6, 2.5 Hz, 1H, H-2), 4.04 (dd, *J* = 9.6, 2.8 Hz, 1H, H-3), 3.76–3.66 (m, 1H, H-7), 2.16 (t, *J* = 2.6 Hz, 1H, CH≡C–), 2.13 (qd, *J* = 6.6, 2.7 Hz, 2H, H-13), 2.01 (s, 3H, Ac–), 1.56–1.31 (m, 8H, –CH₂–), 0.94 (t, *J* = 7.4 Hz, 3H, H₃C–). ¹³C NMR (151 MHz, CD₃OD): δ 172.1, 164.5, 141.3, 111.4, 98.2, 83.6, 81.5, 68.4, 64.3, 52.5, 32.6, 28.5, 27.0, 24.0, 21.3, 17.7, 8.8.

Compound 17a. Alkyne **12** (5 mg, 0.0147 mmol) and compound **28**³⁸ (2.3 mg, 0.006 mmol) were suspended in a mixture of 1:1 ^tBuOH/water (0.1 mL) and stirred magnetically. A freshly prepared solution of sodium ascorbate (3.8 mg, 0.019 mmol) in water was added, followed by addition of a freshly prepared aqueous solution of CuSO₄·5H₂O (1.6 mg, 0.006 mmol). This heterogeneous mixture was stirred vigorously overnight at r.t. The mixture was evaporated under reduced pressure to give a crude product. The latter was purified by silica gel column chromatography using H₂O/MeOH/EtOAc 1:2:10 as the eluent to give a colorless oil which was lyophilized to afford an amorphous solid (4.1 mg, 63%). The product was further purified by RP-HPLC (C₁₈ Column) and the lyophilized to give pure compound **17a** as a white solid. ¹H NMR (600 MHz, D₂O): δ 8.01 (s, 1H), 7.92 (s, 1H), 6.21 (d, *J* = 9.2 Hz, 1H), 5.87–5.83 (m, 3H), 5.60 (t, *J* = 9.3 Hz, 1H), 5.17–5.08 (m, 3H), 4.85–4.77 (m, 2H), 4.15–4.08 (m, 1H), 4.03 (q, *J* = 4.0 Hz, 2H), 3.97 (dt, *J* = 8.1, 4.2 Hz, 2H), 3.93 (dd, *J* = 12.9, 4.2 Hz, 1H), 3.65–3.57 (m, 3H), 2.65 (q, *J* = 7.5 Hz, 4H), 1.96 (s, 3H, –Ac), 1.90 (d, *J* = 3.6 Hz, 6H, –Ac), 1.82 (s, 3H, –Ac), 1.81 (s, 3H, –Ac), 1.57 (dd, *J* = 13.7, 7.5 Hz, 4H, –CH₂–), 1.41 (ddt, *J* = 32.2, 14.1, 7.4 Hz, 8H, –CH₂–), 1.30–1.07 (m, 4H, –CH₂–), 0.70 (t, *J* = 7.4 Hz, 6H, H₃C–). ¹³C NMR [101 MHz, D₂O extracted from heteronuclear single-quantum coherence (HSQC)]: δ 123.2, 122.2, 107.1, 97.5, 85.0, 81.9, 74.1, 73.5, 72.7, 72.1, 72.0, 70.9, 64.4, 63.9, 63.8, 62.7, 62.7, 61.9, 61.9, 59.3, 51.9, 32.3, 28.5, 26.7, 24.2, 23.4, 21.9, 19.9, 19.5, 9.1. MS (ESI, Q-TOF) *m/z*: calcd for C₄₆H₆₆N₈O₁₉ [M – H]⁺, 1033.44; found, 1033.48.

Compound 17b. Alkyne compound **12** (5 mg, 0.0147 mmol) and azide compound **16**²³ (1.47 mg, 0.006 mmol) were suspended in a mixture of 1:1 ^tBuOH/water (0.1 mL) and stirred magnetically. A freshly prepared solution of sodium ascorbate (3.8 mg, 0.019 mmol) in water was added, followed by addition of a freshly prepared aqueous solution of CuSO₄·5H₂O (1.6 mg, 0.006 mmol). This heterogeneous mixture was stirred vigorously overnight at r.t. The mixture was evaporated under reduced pressure to give a crude product. The latter was purified by silica gel column chromatography using H₂O/MeOH/EtOAc 1:2:10 as the eluent to give a colorless oil, which was lyophilized to afford an amorphous solid (3.6 mg, 62%). The product was further purified by RP-HPLC (C₁₈ column) and lyophilized to give pure **17b** as a white solid. ¹H NMR (600 MHz, CD₃OD): δ 7.90 (s, 1H), 7.73 (s, 1H), 5.78 (d, *J* = 4.7 Hz, 2H), 5.64 (d, *J* = 9.3 Hz, 1H), 5.08–5.00 (m, 2H), 4.19–4.15 (m, 1H), 4.12 (t, *J* = 9.6 Hz, 1H), 3.97 (d, *J* = 1.7 Hz, 2H), 3.60–3.55 (m, 2H), 3.33 (d, *J* = 12.5 Hz, 1H), 3.24 (dt, *J* = 3.3, 1.6 Hz, 1H), 2.58 (p, *J* = 6.2 Hz, 4H), 1.78 (d, *J* = 1.3 Hz, 6H, –Nac), 1.55 (dd, *J* = 15.7, 8.1 Hz, 4H, –CH₂–), 1.44–1.20 (m, 12H, –CH₂–), 0.68 (td, *J* = 7.4, 2.3 Hz, 6H, H₃C–). ¹³C NMR (101 MHz, CD₃OD extracted from HSQC): δ 123.2, 122.2, 107.1, 97.5, 85.0, 81.9, 74.1, 73.5, 72.7, 72.1, 72.0, 70.9, 64.4, 63.9, 63.8, 62.7, 62.7, 61.9, 61.9, 59.3, 51.9, 32.3, 28.5, 26.7, 24.2, 23.4, 19.9, 10.0. HRMS (ESI, Q-TOF) *m/z*: calcd for C₄₀H₆₁N₈O₁₆ [M + H]⁺, 909.4206; found, 907.4197.

Compound 19. Alkyne **12** (5 mg, 0.0147 mmol) and azide compound **18**³⁹ (3.5 mg, 0.006 mmol) were suspended in a mixture of 1:1 ^tBuOH/water (0.1 mL) and stirred magnetically. A freshly prepared solution of sodium ascorbate (3.8 mg, 0.019 mmol) in water was added, followed by addition of a freshly prepared aqueous solution of CuSO₄·5H₂O (1.6 mg, 0.006 mmol). This heterogeneous mixture was stirred vigorously overnight at r.t. The mixture was evaporated under reduced pressure to give a crude product. The latter was purified by silica gel column chromatography using H₂O/MeOH/EtOAc 1:2:8 as the eluent to give a colorless oil, which was lyophilized to afford an amorphous solid (4.2 mg, 52%). The product was further purified by RP-HPLC (C₁₈ column) and lyophilized to give pure **19** as a white solid. ¹H NMR (600 MHz, D₂O): δ 8.57 (s, 2H), 8.10 (s, 2H), 7.97 (s, 4H, –Ph–), 5.98 (d, *J* = 9.2 Hz, 2H), 5.88 (d, *J* = 4.2 Hz, 2H), 5.19 (d, *J* = 4.5 Hz, 2H), 4.93 (t, *J* = 10.4 Hz, 2H), 4.48 (t, *J* = 9.8 Hz, 4H), 4.24 (t, *J* = 9.2 Hz, 2H), 4.12 (t, *J* = 4.1 Hz, 2H), 4.05 (t, *J* = 4.3 Hz, 2H), 3.71 (p, *J* = 6.0 Hz, 2H), 3.63 (d, *J* = 12.2 Hz, 2H), 3.36 (dd, *J* = 13.0, 4.2 Hz, 2H), 2.78 (t, *J* = 7.2 Hz, 4H), 1.98 (s, 6H, –Nac), 1.71 (dq, *J* = 13.5, 7.3 Hz, 4H, –CH₂–), 1.51 (ddd, *J* = 27.6, 15.0, 7.5 Hz, 8H, –CH₂–), 1.36 (dt, *J* = 21.6, 14.7, 7.1 Hz, 4H, –CH₂–), 0.80 (t, *J* = 7.4 Hz, 6H, H₃C–). ¹³C NMR (101 MHz, D₂O extracted from HSQC): δ 126.5, 122.6, 122.3, 106.8, 97.9, 87.3, 82.0, 76.9, 73.6, 72.5, 64.5, 61.6, 59.7, 59.6, 52.0, 32.5, 28.5, 26.7, 24.4, 23.5, 21.9, 9.0. HRMS (ESI, Q-TOF) *m/z*: calcd for C₅₆H₇₄N₁₄O₂₀ [M – 2H]²⁺, 631.2607; found, 631.2604.

Compound 21. Alkyne **12** (5 mg, 0.0147 mmol) and azide **20** (5.7 mg, 0.006 mmol) were suspended in a mixture of 1:1 ^tBuOH/water (0.1 mL) and stirred magnetically. A freshly prepared solution of sodium ascorbate (3.8 mg, 0.019 mmol) in water was added, followed by addition of a freshly prepared aqueous solution of CuSO₄·5H₂O (1.6 mg, 0.006 mmol). This heterogeneous mixture was stirred vigorously overnight at r.t. The mixture was evaporated under reduced pressure to give a crude product. The latter was purified by silica gel column chromatography using H₂O/MeOH/EtOAc 1:3:8 as the eluent to give a light-yellow oil, which was lyophilized to afford an amorphous solid (4.8 mg, 41%). The product was further purified by RP-HPLC (HILIC Column) and lyophilized to give pure **21** as a white solid. ¹H NMR (600 MHz, CD₃OD): δ 8.53 (s, 2H), 8.47 (s, 2H), 8.13 (s, 2H), 8.05–7.83 (m, 8H, –Ph–), 5.99 (dd, *J* = 4.8, 1.3 Hz, 2H), 5.89 (d, *J* = 9.2 Hz, 1H), 5.26 (d, *J* = 2.2 Hz, 1H), 4.85–4.80 (m, 2H), 4.66–4.58 (m, 1H), 4.45 (ddd, *J* = 10.4, 4.1, 2.1 Hz, 2H), 4.38 (dd, *J* = 10.3, 8.9 Hz, 1H), 4.25 (ddd, *J* = 10.4, 4.2, 2.1 Hz, 2H), 4.22–4.14 (m, 2H), 3.91 (ddd, *J* = 4.9, 2.6, 1.1 Hz, 1H), 3.79 (p, *J* = 5.9 Hz, 2H), 3.63 (dt, *J* = 13.1, 2.4 Hz, 2H), 3.39–3.36 (m, 4H), 3.31–3.29 (m, 2) 2.81 (td, *J* = 7.5, 2.2 Hz, 4H), 1.99 (s, 6H, –Nac), 1.76 (tq, *J* = 13.7, 6.4 Hz, 4H, –CH₂–), 1.67–1.45 (m, 12H,

–CH₂–), 0.89 (t, *J* = 7.4 Hz, 6H, H₃C–). ¹³C NMR (151 MHz, CD₃OD, extracted from HSQC): δ 129.4, 129.4, 126.3, 126.3, 123.1, 122.1, 121.9, 107.1, 98.1, 87.5, 82.1, 78.6, 76.2, 70.9, 70.9, 64.3, 63.7, 63.1, 60.7, 52.3, 32.6, 28.1, 26.7, 25.8, 23.9, 21.2, 9.3. MS (ESI, Q-TOF) *m/z*: calcd for C₇₂H₉₂N₂₀O₂₄ [M – 2H]⁺, 809.33; found, 809.36.

Compound 22. Alkyne **12** (5 mg, 0.0147 mmol) and azide **18** (26 mg, 0.0441 mmol) were suspended in a mixture of 1:1 BuOH/water (1 mL) and stirred magnetically. A freshly prepared solution of sodium ascorbate (0.87 mg, 0.004 mmol) in water was added, followed by addition of a freshly prepared aqueous solution of CuSO₄·5H₂O (0.6 mg, 0.002 mmol). This heterogeneous mixture was stirred vigorously for 6 h at r.t. The mixture was evaporated under reduced pressure to give a crude product. The latter was purified by silica gel column chromatography using H₂O/MeOH/EtOAc 1:2:10 as the eluent to give a colorless oil, which was lyophilized to afford **22** (6.1 mg, 45%) as a white solid. ¹H NMR (600 MHz, CD₃OD): δ 8.53 (s, 2H), 8.47 (s, 2H), 8.13 (s, 2H), 8.00–7.95 (m, 8H, –Ph–), 6.00 (d, *J* = 4.5 Hz, 2H), 5.90 (s, 1H), 5.88 (s, 1H), 5.26 (d, *J* = 2.5 Hz, 2H), 4.64 (d, *J* = 10.3 Hz, 1H), 4.45 (ddd, *J* = 10.3, 3.9, 2.0 Hz, 2H), 4.39 (d, *J* = 9.0 Hz, 1H), 4.25 (ddd, *J* = 10.4, 4.0, 2.0 Hz, 2H), 4.20 (d, *J* = 10.4 Hz, 2H), 3.95–3.90 (m, 1H), 3.78 (dt, *J* = 11.6, 5.8 Hz, 2H), 3.66–3.63 (m, 2H), 3.63–3.61 (m, 2H), 3.40–3.36 (m, 4H), 3.31–3.29 (m, 2H), 2.83–2.76 (m, 4H), 1.99 (s, 6H, –NAC), 1.82–1.71 (m, 4H, –CH₂–), 1.64–1.46 (m, 12H, –CH₂–), 0.89 (t, *J* = 7.4 Hz, 6H, H₃C–). ¹³C NMR (151 MHz, CD₃OD): δ 171.96, 146.61, 130.20, 125.85, 122.29, 121.32, 108.56, 97.76, 90.81, 88.01, 81.16, 77.51, 76.67, 74.43, 74.01, 73.98, 73.05, 64.17, 61.97, 61.82, 60.05, 60.00, 51.94, 32.81, 29.11, 27.07, 24.82, 24.19, 21.19, 8.75. HRMS (ESI, Q-TOF) *m/z*: calcd for C₅₆H₇₆N₁₄O₂₀ [M – 2H]⁺, 631.27; found, 631.30.

Compound 24. Compound **22** (6.0 mg, 0.0066 mmol) and compound **23** (0.35 mg, 0.0022 mmol) were suspended in a mixture of 1:1 BuOH/water (0.1 mL) and stirred magnetically. A freshly prepared solution of sodium ascorbate (1.3 mg, 0.0066 mmol) in water was added, followed by addition of a freshly prepared aqueous solution of CuSO₄·5H₂O (0.55 mg, 0.0022 mmol). This heterogeneous mixture was stirred vigorously overnight at r.t. The mixture was evaporated under reduced pressure to give a crude product. The latter was purified by silica gel column chromatography using H₂O/MeOH/EtOAc 2:3:8 as the eluent to give a light-yellow oil, which was lyophilized to afford an amorphous solid (1.2 mg, 28%). The product was further purified by RP-HPLC (HILIC column) and lyophilized to give pure **24** as a white solid. ¹H NMR (600 MHz, CD₃OD): δ 8.71 (s, 2H), 8.53 (s, 2H), 8.52 (s, 2H), 8.11 (s, 2H), 7.98 (s, 8H, –Ph–), 7.64 (s, 2H, –Ph–), 5.98 (d, *J* = 8.9 Hz, 2H), 5.87 (d, *J* = 9.2 Hz, 2H), 5.24 (d, *J* = 2.2 Hz, 2H), 4.51–4.47 (m, 2H), 4.46–4.42 (m, 2H), 4.43–4.39 (m, 4H), 4.39–4.35 (m, 4H), 4.26–4.22 (m, 4H), 4.19–4.14 (m, 4H), 3.91–3.89 (m, 2H), 3.78–3.73 (m, 2H), 3.67–3.59 (m, 4H), 2.82–2.74 (m, 4H), 1.97 (s, 3H, –NAC), 1.96 (s, 3H, –NAC), 1.84–1.68 (m, 4H, –CH₂–), 1.62–1.40 (m, 12H, –CH₂–), 0.87 (t, *J* = 7.4 Hz, 6H, H₃C–). ¹³C NMR (151 MHz, CD₃OD extracted from HSQC): δ 127.5, 122.9, 122.9, 122.9, 121.7, 113.6, 108.6, 108.6, 97.8, 89.8, 81.16, 77.51, 73.7, 73.4, 64.9, 61.8, 61.8, 61.2, 60.1, 51.94, 32.8, 29.1, 27.1, 24.8, 24.2, 21.4, 21.2, 9.8. MS (ESI, Q-TOF) *m/z*: calcd for C₈₈H₁₀₈N₂₆O₃₀ [M – 2H]⁺, 1003.4; found, 1003.9.

Compound 27. Compound **26**³⁴ (700 mg, 1.35 mmol) and 1,4-diethynylbenzene (340 mg, 2.70 mmol) were dissolved in DMF (0.9 mL). Then, an aqueous solution of CuSO₄·5H₂O (17 mg in 50 μL of water, 68.5 μmol) and Na ascorbate (27 mg in 50 μL of water, 135 μmol) was added to the resulting mixture. Finally, tris((1-benzyl-4-triazolyl)methyl)amine (36 mg, 202.5 μmol) was added, and the mixture was heated by microwave irradiation at 80 °C for 50 min. TLC indicated complete conversion of the reaction. The mixture was dried under vacuum, and the residue was purified by column chromatography (EA/PE 1:5) to afford **27** as a colorless syrup (516 mg, 60%). ¹H NMR (600 MHz, CDCl₃): δ 8.17 (dd, *J* = 8.4, 1.3 Hz, 4H), 7.98 (s, 4H), 7.96 (s, 1H), 7.79–7.74 (m, 2H), 7.63 (ddt, *J* = 7.4, 6.2, 1.1 Hz, 4H), 5.94 (dd, *J* = 10.5, 9.3 Hz, 2H), 4.74 (d, *J* = 10.0

Hz, 1H), 4.70 (t, *J* = 3.5 Hz, 1H), 4.68 (t, *J* = 3.5 Hz, 1H), 4.65 (dd, *J* = 12.3, 3.2 Hz, 1H), 4.42 (dd, *J* = 12.3, 3.8 Hz, 1H), 3.70 (s, 1H), 1.46 (s, 9H), 0.21 (s, 6H). ¹³C NMR (101 MHz, CDCl₃): δ 169.29, 169.19, 165.79, 147.29, 133.36, 129.84, 129.68, 129.21, 128.47, 126.15, 119.92, 89.65, 75.81, 73.17, 71.86, 69.38, 62.86, 60.79, 29.67, 20.57, 20.27, 18.44, 10.97, –0.04. MS (ESI, Q-TOF) *m/z*: calcd for C₃₆H₃₉N₃O₇Si [M + H]⁺, 654.26; found, 524.24.

Compound 29. To a solution of **28** (72.2 mg, 0.203 mmol, 1.0 equiv) and **27** (278 mg, 0.436 mmol, 2.15 equiv) in DMF (0.9 mL), an aqueous solution of Na ascorbate (4 mg, 0.1 equiv in 50 μL water) and CuSO₄·5H₂O (2.53 mg, 0.05 equiv in 50 μL water) was added. The resulting system reacted at 80 °C with microwave irradiation for 1 h. TLC showed that most of **28** was consumed, and a new spot was formed. The solvent was removed in vacuo. The residue was dissolved in DCM/MeOH (80/1), and a minimal amount of silica was added. After removal of the solvents, it was purified by column chromatography (DCM/MeOH = 90/1) to afford the product as a white solid (220 mg, 0.132 mmol, 65%). ¹H NMR (600 MHz, DMSO-*d*₆): δ 9.01 (s, 1H, H-triazole), 9.00 (s, 1H, H-triazole), 8.99 (s, 1H, H-triazole), 8.80 (s, 1H, H-triazole), 8.00–7.90 (m, 12H, H-Ph), 7.75–7.74 (d, *J* = 7.9 Hz, 4H, H-Ph), 7.62 (t, *J* = 7.4 Hz, 2H, H-Ph), 7.57 (t, *J* = 7.4 Hz, 2H, H-Ph), 7.48 (t, *J* = 7.9, 7.7 Hz, 4H, H-Ph), 7.41 (t, *J* = 7.9, 7.7 Hz, 4H, H-Ph), 6.59 (d, *J* = 9.2 Hz, 1H), 6.48 (d, *J* = 9.2 Hz, 2H), 6.21 (t, *J* = 9.5 Hz, 2H), 6.10 (t, *J* = 9.8 Hz, 1H), 5.85 (t, *J* = 9.2 Hz, 1H), 5.75 (m, 2H), 5.64 (dd, *J* = 10.1, 2.7 Hz, 2H), 5.20 (t, *J* = 10.3 Hz, 1H), 5.04–5.01 (m, 1H), 4.33 (m, 2H), 4.30 (t, *J* = 6.2, 6.4 Hz, 2H), 3.97 (m, 2H), 3.91 (dd, *J* = 10.3, 6.5 Hz, 2H), 3.79 (dd, *J* = 10.3, 6.1 Hz, 2H), 1.96 (s, 3H, H-OAc), 1.85 (s, 3H, H-OAc), 1.84 (s, 3H, H-OAc), 0.86 (s, 18H, Si(CH₃)₂C(CH₃)₃), 0.06 (s, 6H, Si(CH₃)₂C(CH₃)₃), 0.05 (s, 6H, Si(CH₃)₂C(CH₃)₃). ¹³C NMR (151 MHz, DMSO-*d*₆): δ 121.2, 120.9, 122.0, 126.4, 126.3, 129.8, 129.5, 129.2, 134.1, 134.3, 129.3, 84.6, 85.5, 69.9, 72.4, 70.9, 75.3, 59.9, 74.1, 65.9, 78.1, 62.4, 61.9, 61.9, 20.8, 20.4, 26.3. HRMS (ESI, Q-TOF) *m/z*: calcd for C₈₄H₉₅N₁₂O₁₂Si₂ [M + H]⁺, 1663.627; found, 1663.629.

Compound 30. To a solution of compound **29** (80 mg, 48 μmol, 1.0 equiv) in dry DCM (5 mL) and dry pyridine (0.5 mL), triflic anhydride (162 μL, 962 μmol, 20.0 equiv) was added dropwise at 0 °C. The resulting mixture was stirred at 4 °C overnight. TLC indicated that the substrate was converted to the (triflate) intermediate. Then, KHSO₄ was added to quench the reaction. DCM (15 mL) was added to extract the (triflate) intermediate. The organic layer was washed with HCl (2 N, 3 × 10 mL), water (3 × 10 mL), and brine (10 mL) and dried with sodium sulfate. After removal of the solvent, the compound was directly used for the next step without further purification. It was dissolved in DMF (5 mL), and NaN₃ (32 mg, 480 μmol, 10.0 equiv) was added. The mixture was stirred at r.t. for 24 h. Then, the solvent was removed in vacuo. DCM and methanol were added, followed by a minimal amount of silica gel. After removal of the solvents, the mixture was purified by column chromatography (DCM/MeOH = 100/1) to afford the product as a white solid (47 mg, 59%). ¹H NMR (600 MHz, DMSO-*d*₆): δ 9.03 (dd, 2H, H-triazole), 8.99 (s, 1H, H-triazole), 8.78 (s, 1H, H-triazole), 7.97–7.90 (m, 12H, H-Ph), 7.67–7.63 (m, 6H, H-Ph), 7.56 (t, *J* = 7.4 Hz, 1H), 7.51 (t, *J* = 7.9, 7.7 Hz, 4H), 7.40 (t, *J* = 7.9, 7.7 Hz, 4H), 6.61–6.57 (m, 3H), 6.09 (t, *J* = 9.8 Hz, 1H), 6.05–6.01 (m, 4H), 5.84 (t, *J* = 9.2 Hz, 1H), 5.20 (t, *J* = 10.3 Hz, 1H), 5.03–5.00 (m, 1H), 4.27–4.24 (m, 2H), 4.19–4.16 (m, 2H), 3.98–3.91 (m, 6H), 1.94 (s, 3H, H-OAc), 1.83 (s, 3H, H-OAc), 1.82 (s, 3H, H-OAc), 0.88 (s, 18H, Si(CH₃)₂C(CH₃)₃), 0.06 (s, 6H, Si(CH₃)₂C(CH₃)₃), 0.02 (s, 6H, Si(CH₃)₂C(CH₃)₃). ¹³C NMR (151 MHz, DMSO-*d*₆): δ 134.5, 134.5, 129.8, 129.6, 129.4, 129.3, 126.4, 122.1, 122.1, 121.2, 129.8, 84.6, 77.0, 74.3, 74.1, 72.3, 71.9, 70.9, 62.7, 59.9, 59.9, 26.3, 20.8, 20.4. HRMS (ESI, Q-TOF) *m/z*: calcd for C₈₄H₉₃N₁₈O₁₉Si₂ [M + H]⁺, 1713.640; found, 1713.644.

Compound 20. The protected substrate **30** (58 mg, 0.034 mmol) was suspended or dissolved in methanol. NaOMe (3.7 mg, 0.068 mmol) was added to obtain a basic pH (pH ≈ 12). The reaction mixture was stirred at r.t., and it was monitored by TLC. After disappearance of the substrate, the reaction mixture was neutralized

with 6 M HCl (1 mL) to obtain pH < 5. The mixture was filtered, and the solvent was evaporated in vacuo, and the residue was subjected to purification by column chromatography (EA/MeOH/H₂O = 15:2:1) to afford the product as a white solid (15 mg, 15.9 μ mol, 47%). ¹H NMR (600 MHz, DMSO-*d*₆): δ 9.01 (s, 1H, H-triazole), 8.91 (s, 2H, H-triazole), 8.82 (s, 1H, H-triazole), 7.96–8.01 (m, 8H, H-Ph), 6.06 (d, *J* = 5.5 Hz, 1H), 5.91 (dd, *J* = 14.0, 6.5 Hz, 3H), 5.77 (d, *J* = 5.8 Hz, 1H), 5.68 (d, *J* = 9.1 Hz, 2H), 4.99–4.95 (m, 2H), 4.63 (t, *J* = 10.2 Hz, 1H), 4.27 (q, *J* = 9.1 Hz, 1H), 4.09 (dt, *J* = 15.4, 9.0 Hz, 1H), 3.90 (td, *J* = 8.7 Hz, 2H), 3.70 (q, *J* = 8.0 Hz, 2H), 3.54 (q, *J* = 10.0, 8.4 Hz, 6H). ¹³C NMR (151 MHz, DMSO): δ 121.3, 121.3, 122.1, 126.4, 126.4, 74.2, 84.6, 70.9, 72.3, 60.7, 73.2, 70.9, 60.1, 77.9, 62.3. HRMS (ESI, Q-TOF) *m/z*: calcd for C₃₈H₄₂N₁₈O₁₂ [M + H]⁺, 943.323; found, 943.327.

Molecular Docking. The structures of OCM were generated in ChemDraw 19.0 and subsequently imported in Chem3D 19.0 and saved as mol2 file. From this starting point, a library of conformers was generated using Omega2 software (3.1.1.2., OpenEye Scientific Software, Inc., Santa Fe, NM, USA; www.eyesopen.com)⁴⁰ using default settings, which was limited to 200 conformers. Pdb 4B7Q was the input for MAKE RECEPTOR (Release 3.3.1.2, OpenEye Scientific Software, Inc., Santa Fe, NM, USA; www.eyesopen.com). The grid box around the NA tetramer was generated automatically and enlarged to incorporate the entire protein. For “cavity detection” slow and effective “molecular” method was used for detection of binding sites. Inner and outer contours of the grid box were also calculated automatically using “balanced” settings for “site shape potential” calculations. Docking was performed with OEDocking 3.3.1.2 using the hybrid program.⁴¹ A hit list of top 100 ranked molecules was retrieved, and the best ranked hybrid-calculated poses were inspected visually and used for analysis and representation. The results were evaluated in visualization software VIDA 4.4.0 (OpenEye Scientific Software, Inc., Santa Fe, NM, USA).

Recombinant Proteins, Cells, and Virus. Construction of recombinant soluble tetrameric N9 (A/Anascrecca/Spain/1460/2008(H7N9), GenBank accession no. HQ244409.1) and N1 (A/Wisconsin/09/2013(H1N1), GenBank accession no. AGV29183.1) expression constructs was described previously.^{26,29} NA expression plasmids were transfected into HEK293T cells (ATCC), and recombinant soluble NA proteins were purified from the cell culture supernatants using Strep-Tactin beads (IBA) as described previously.^{42,43} Influenza virus A/Netherlands/602/2009 (Neth09H1N1) was characterized previously.⁴⁴ Approximately ~70% confluent MDCK-II cells (ATCC) were infected at a multiplicity of infection of 0.01 TCID₅₀ units per cell in Opti-MEM (Gibco) containing 1 μ g/mL of TPCK-trypsin. The supernatant was harvested after 48 h of incubation at 37 °C, and cell debris was removed by centrifugation (10 min at 2000 rpm). The virus was aliquoted and stored at –80 °C until use.

MUNANA Assay. The inhibitory activities of different compounds were assessed by using the synthetic monovalent substrate MUNANA similarly as described previously.⁴³ Briefly, compounds were diluted in the reaction buffer (50 mM Tris-HCl, 4 mM CaCl₂, pH 6.0) and subsequently serially diluted 1:2 in a flat-bottom 96-well black plate, followed by the addition of a similar volume of reaction buffer containing a fixed, non-saturated amount of NA protein or virus. Subsequently, 200 μ M MUNANA diluted in the reaction buffer was added to each well to a final concentration of 100 μ M, mixed well, and incubated at 37 °C for 60 min. The reaction was terminated by addition of the stop solution (0.1 M glycine, 25% ethanol, pH 10.7). The fluorescence signal was immediately determined in relative fluorescence units by using a FLUOstar OPTIMA plate reader with the excitation and emission wavelengths at 340 and 490 nm, respectively.

CPE Assay Experiments. Compounds were serially diluted in Opti-MEM starting at 5 μ M, followed by the addition of 50TCID₅₀ units of H1N1 pdm09. Subsequently, the virus and compound mixtures were incubated on a monolayer of MDCKII cells in a 96-well plate at 37 °C and 5% CO₂ for 4 days. After the incubation, the cell cultures were visually inspected using a microscope for virally induced

CPE and the inhibition thereof by the compounds. The lowest concentration for each compound that inhibits the formation of CPE was used to assess their inhibitory activities (*N* = 8–16).

BLI Binding Assay. All BLI experiments were performed using OctetRED384 (FortéBio) as described previously.^{3,45} All the experiments were carried out in phosphate-buffered saline with calcium and magnesium (Lonza) at 30 °C and with shaking of plates at 1000 rpm. In short, streptavidin sensors were loaded to saturation with biotinylated lysosomal-associated membrane glycoprotein 1 (LAMP1) containing increased levels of α 2,6-linked sialic acids.⁴⁵ Subsequently, sensors were moved to wells containing a mixture of the virus and variable concentrations of the indicated compounds. When indicated, oseltamivir carboxylate (OC; 10 μ M final concentration, gift from Roche) was added to this mixture to inhibit NA activity. As a control, binding was analyzed in the absence of inhibitory compounds or in the presence of OC only. For the virus re-binding assay, sensors bound with viruses were moved to wells carrying 0.1 M glycine (pH = 2) three times for 5 s in order to remove all bound viruses after a virus binding step as described above. Afterward, the sensors were dipped into virus-containing wells in the presence of 10 μ M OC to check virus binding to the remaining sialoglycan receptors.

■ ASSOCIATED CONTENT

Supporting Information

The Supporting Information is available free of charge at <https://pubs.acs.org/doi/10.1021/acs.jmedchem.2c00319>.

Inhibition data, modeling poses, NMR spectra, and HPLC chromatograms (PDF)

Simplified molecular-input line-entry system (CSV)

N9 OCM complex (PDB)

■ AUTHOR INFORMATION

Corresponding Authors

Cornelis A. M. de Haan – Section Virology, Division Infectious Diseases and Immunology, Faculty Veterinary Medicine, Utrecht University, Utrecht NL-3508 TB, The Netherlands; Email: c.a.m.dehaan@uu.nl

Roland J. Pieters – Department of Chemical Biology & Drug Discovery, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht NL-3508 TB, The Netherlands; orcid.org/0000-0003-4723-3584; Email: r.j.pieters@uu.nl

Authors

Xuan Wei – Department of Chemical Biology & Drug Discovery, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht NL-3508 TB, The Netherlands

Wenjuan Du – Section Virology, Division Infectious Diseases and Immunology, Faculty Veterinary Medicine, Utrecht University, Utrecht NL-3508 TB, The Netherlands

Margherita Duca – Department of Chemical Biology & Drug Discovery, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht NL-3508 TB, The Netherlands

Guangyun Yu – Department of Chemical Biology & Drug Discovery, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht NL-3508 TB, The Netherlands

Erik de Vries – Section Virology, Division Infectious Diseases and Immunology, Faculty Veterinary Medicine, Utrecht University, Utrecht NL-3508 TB, The Netherlands

Complete contact information is available at:

<https://pubs.acs.org/10.1021/acs.jmedchem.2c00319>

Author Contributions

The manuscript was written through contributions of all authors. All authors approved of the final version of the manuscript.

Notes

The authors declare no competing financial interest.

ACKNOWLEDGMENTS

X.W. and W.D. gratefully acknowledge financial support by a scholarship from the China Scholarship Council CSC (<http://www.csc.edu.cn/>), files nos. 201606230221 and 201603250057, respectively. The academic license for OpenEye software was kindly provided by OpenEye Scientific Software Inc. to the laboratory of Roland Pieters.

ABBREVIATIONS

BLI, biolayer interferometry; CPE, cytopathic effects; CuAAC, copper-catalyzed azide alkyne cycloaddition; HA, hemagglutinin; IAV, Influenza A virus; MDCK, Madin–Darby canine kidney; MUNANA, 2'-(4-methylumbelliferyl)- α -D-N-acetylneuraminic acid; NA, neuraminidase; PEG, poly ethylene glycol; SPR, surface plasmon resonance; TCID, tissue culture infectious dose; Troc, 2,2,2-trichloroethoxycarbonyl

REFERENCES

- (1) Palese, P. Influenza: Old and New Threats. *Nat. Med.* **2004**, *10*, S82–S87.
- (2) Richard, M.; Fouchier, R. A. M. Influenza A Virus Transmission via Respiratory Aerosols or Droplets as It Relates to Pandemic Potential. *FEMS Microbiol. Rev.* **2015**, *40*, 68–85.
- (3) Guo, H.; Rabouw, H.; Slomp, A.; Dai, M.; van der Vegt, F.; van Lent, J. W. M.; McBride, R.; Paulson, J. C.; de Groot, R. J.; van Kuppeveld, F. J. M.; de Vries, E.; de Haan, C. A. M. Kinetic Analysis of the Influenza A Virus HA/NA Balance Reveals Contribution OfNA to Virus- Receptor Binding and NA-Dependent Rolling on Receptor-Containing Surfaces. *PLoS Pathog.* **2018**, *14*, No. e1007233.
- (4) de Vries, E.; Du, W.; Guo, H.; de Haan, C. A. M. Influenza A Virus Hemagglutinin–Neuraminidase–Receptor Balance: Preserving Virus Motility. *Trends Microbiol.* **2020**, *28*, 57–67.
- (5) de Graaf, M.; Fouchier, R. A. M. Role of Receptor Binding Specificity in Influenza A Virus Transmission and Pathogenesis. *EMBO J.* **2014**, *33*, 823–841.
- (6) Ji, Y.; White, Y. J.; Hadden, J. A.; Grant, O. C.; Woods, R. J. New Insights into Influenza A Specificity: An Evolution of Paradigms. *Curr. Opin. Struct. Biol.* **2017**, *44*, 219–231.
- (7) Hamilton, B. S.; Whittaker, G. R.; Daniel, S. Influenza Virus-Mediated Membrane Fusion: Determinants of Hemagglutinin Fusogenic Activity and Experimental Approaches for Assessing Virus Fusion. *Viruses* **2012**, *4*, 1144–1168.
- (8) von Itzstein, M. The War against Influenza: Discovery and Development of Sialidase Inhibitors. *Nat. Rev. Drug Discovery* **2007**, *6*, 967–974.
- (9) Moscona, A. Oseltamivir Resistance — Disabling Our Influenza Defenses. *N. Engl. J. Med.* **2005**, *353*, 2633–2636.
- (10) Kim, J.-H.; Resende, R.; Wennekes, T.; Chen, H.-M.; Bance, N.; Buchini, S.; Watts, A. G.; Pilling, P.; Streltsov, V. A.; Petric, M.; Liggins, R.; Barrett, S.; McKimm-Breschkin, J. L.; Niikura, M.; Withers, S. G. Mechanism-Based Covalent Neuraminidase Inhibitors with Broad-Spectrum Influenza Antiviral Activity. *Science* **2013**, *340*, 71–75.
- (11) Fu, L.; Bi, Y.; Wu, Y.; Zhang, S.; Qi, J.; Li, Y.; Lu, X.; Zhang, Z.; Lv, X.; Yan, J.; Gao, G. F.; Li, X. Structure-Based Tetravalent Zanamivir with Potent Inhibitory Activity against Drug-Resistant Influenza Viruses. *J. Med. Chem.* **2016**, *59*, 6303–6312.
- (12) Wei, X.; Pieters, R. J. Multivalency Effects in Neuraminidase Inhibitor Design for Influenza Virus. *Arkivoc* **2021**, *2021*, 297–312.
- (13) Harris, A.; Cardone, G.; Winkler, D. C.; Heymann, J. B.; Brecher, M.; White, J. M.; Steven, A. C. Influenza Virus Pleiomorphism Characterized by Cryoelectron Tomography. *Proc. Natl. Acad. Sci. U.S.A.* **2006**, *103*, 19123–19127.
- (14) Honda, T.; Masuda, T.; Yoshida, S.; Arai, M.; Kaneko, S.; Yamashita, M. Synthesis and Anti-Influenza Virus Activity of 7-O-Alkylated Derivatives Related to Zanamivir. *Bioorg. Med. Chem. Lett.* **2002**, *12*, 1925–1928.
- (15) Macdonald, S. J. F.; Watson, K. G.; Cameron, R.; Chalmers, D. K.; Demaine, D. A.; Fenton, R. J.; Gower, D.; Hamblin, J. N.; Hamilton, S.; Hart, G. J.; Inglis, G. G. A.; Jin, B.; Jones, H. T.; McConnell, D. B.; Mason, A. M.; Nguyen, V.; Owens, I. J.; Parry, N.; Reece, P. A.; Shanahan, S. E.; Smith, D.; Wu, W.-Y.; Tucker, S. P. Potent and Long-Acting Dimeric Inhibitors of Influenza Virus Neuraminidase Are Effective at a Once-Weekly Dosing Regimen. *Antimicrob. Agents Chemother.* **2004**, *48*, 4542–4549.
- (16) Watson, K. G.; Cameron, R.; Fenton, R. J.; Gower, D.; Hamilton, S.; Jin, B.; Krippner, G. Y.; Luttick, A.; McConnell, D.; MacDonald, S. J. F.; Mason, A. M.; Nguyen, V.; Tucker, S. P.; Wu, W.-Y. Highly Potent and Long-Acting Trimeric and Tetrameric Inhibitors of Influenza Virus Neuraminidase. *Bioorg. Med. Chem. Lett.* **2004**, *14*, 1589–1592.
- (17) Macdonald, S. J. F.; Cameron, R.; Demaine, D. A.; Fenton, R. J.; Foster, G.; Gower, D.; Hamblin, J. N.; Hamilton, S.; Hart, G. J.; Hill, A. P.; Inglis, G. G. A.; Jin, B.; Jones, H. T.; McConnell, D. B.; McKimm-Breschkin, J.; Mills, G.; Nguyen, V.; Owens, I. J.; Parry, N.; Shanahan, S. E.; Smith, D.; Watson, K. G.; Wu, W.-Y.; Tucker, S. P. Dimeric Zanamivir Conjugates with Various Linking Groups Are Potent, Long-Lasting Inhibitors of Influenza Neuraminidase Including H5N1 Avian Influenza. *J. Med. Chem.* **2005**, *48*, 2964–2971.
- (18) Wen, W.-H.; Lin, M.; Su, C.-Y.; Wang, S.-Y.; Cheng, Y.-S. E.; Fang, J.-M.; Wong, C.-H. Synergistic Effect of Zanamivir-Porphyrin Conjugates on Inhibition of Neuraminidase and Inactivation of Influenza Virus. *J. Med. Chem.* **2009**, *52*, 4903–4910.
- (19) Fraser, B. H.; Hamilton, S.; Krause-Heuer, A. M.; Wright, P. J.; Greguric, I.; Tucker, S. P.; Draffan, A. G.; Fokin, V. V.; Sharpless, K. B. Synthesis of 1,4-Triazole Linked Zanamivir Dimers as Highly Potent Inhibitors of Influenza A and B. *Med. Chem. Commun.* **2013**, *4*, 383–386.
- (20) Tarbet, E. B.; Hamilton, S.; Vollmer, A. H.; Luttick, A.; Ng, W. C.; Pryor, M.; Hurst, B. L.; Crawford, S.; Smee, D. F.; Tucker, S. P. A Zanamivir Dimer with Prophylactic and Enhanced Therapeutic Activity against Influenza Viruses. *J. Antimicrob. Chemother.* **2014**, *69*, 2164–2174.
- (21) Yang, Z.-L.; Zeng, X.-F.; Liu, H.-P.; Yu, Q.; Meng, X.; Yan, Z.-L.; Fan, Z.-C.; Xiao, H.-X.; Iyer, S. S.; Yang, Y.; Yu, P. Synthesis of Multivalent Difluorinated Zanamivir Analogs as Potent Antiviral Inhibitors. *Tetrahedron Lett.* **2016**, *57*, 2579–2582.
- (22) Lu, W.; Du, W.; Somovilla, V. J.; Yu, G.; Haksar, D.; de Vries, E.; Boons, G.-J.; de Vries, R. P.; de Haan, C. A. M.; Pieters, R. J. Enhanced Inhibition of Influenza A Virus Adhesion by Di- and Trivalent Hemagglutinin Inhibitors. *J. Med. Chem.* **2019**, *62*, 6398–6404.
- (23) Yu, G.; Vicini, A. C.; Pieters, R. J. Assembly of Divalent Ligands and Their Effect on Divalent Binding to *Pseudomonas Aeruginosa* Lectin LecA. *J. Org. Chem.* **2019**, *84*, 2470–2488.
- (24) Bhatt, B.; Böhm, R.; Kerry, P. S.; Dyason, J. C.; Russell, R. J. M.; Thomson, R. J.; Von Itzstein, M. Exploring the Interactions of Unsaturated Glucuronides with Influenza Virus Sialidase. *J. Med. Chem.* **2012**, *55*, 8963–8968.
- (25) Gubareva, L. V.; Sleeman, K.; Guo, Z.; Yang, H.; Hodges, E.; Davis, C. T.; Baranovich, T.; Stevens, J. Drug Susceptibility Evaluation of an Influenza A(H7N9) Virus by Analyzing Recombinant Neuraminidase Proteins. *J. Infect. Dis.* **2017**, *216*, S566–S574.
- (26) Dai, M.; McBride, R.; Dortmans, J. C. F. M.; Peng, W.; Bakkers, M. J. G.; de Groot, R. J.; van Kuppeveld, F. J. M.; Paulson, J. C.; de Vries, E.; de Haan, C. A. M. Mutation of the Second Sialic Acid-Binding Site, Resulting in Reduced Neuraminidase Activity, Preceded

the Emergence of H7N9 Influenza A Virus. *J. Virol.* **2017**, *91*, No. e00049.

(27) van der Vries, E.; Collins, P. J.; Vachieri, S. G.; Xiong, X.; Liu, J.; Walker, P. A.; Haire, L. F.; Hay, A. J.; Schutten, M.; Osterhaus, A. D. M. E.; Martin, S. R.; Boucher, C. A. B.; Skehel, J. J.; Gamblin, S. J. H1N1 Pandemic Influenza Virus: Resistance of the I223R Neuraminidase Mutant Explained by Kinetic and Structural Analysis. *PLoS Pathog.* **2012**, *8*, No. e1002914.

(28) Pertici, F.; de Mol, N. J.; Kemmink, J.; Pieters, R. J. Optimizing Divalent Inhibitors of Pseudomonas Aeruginosa Lectin LecA by Using A Rigid Spacer. *Chem.—Eur. J.* **2013**, *19*, 16923–16927.

(29) Dai, M.; Du, W.; Martínez-Romero, C.; Leenders, T.; Wennekes, T.; Rimmelzwaan, G. F.; van Kuppeveld, F. J. M.; Fouchier, R. A. M.; Garcia-Sastre, A.; de Vries, E.; de Haan, C. A. M. Analysis of the Evolution of Pandemic Influenza a(H1N1) Virus Neuraminidase Reveals Entanglement of Different Phenotypic Characteristics. *mBio* **2021**, *12*, No. e00287.

(30) Nason, R.; Büll, C.; Konstantinidi, A.; Sun, L.; Ye, Z.; Halim, A.; Du, W.; Sorensen, D. M.; Durbesson, F.; Furukawa, S.; Mandel, U.; Joshi, H. J.; Dworkin, L. A.; Hansen, L.; David, L.; Iverson, T. M.; Bensing, B. A.; Sullam, P. M.; Varki, A.; de Vries, E.; de Haan, C. A. M.; Vincetelli, R.; Henrissat, B.; Vakhrushev, S. Y.; Clausen, H.; Narimatsu, Y. Display of the Human Mucinome with Defined O-Glycans by Gene Engineered Cells. *Nat. Commun.* **2021**, *12*, 4070.

(31) Yan, Z.-L.; Liu, A.-Y.; Wei, X.-X.; Zhang, Z.; Qin, L.; Yu, Q.; Yu, P.; Lu, K.; Yang, Y. Divalent Oseltamivir Analogues as Potent Influenza Neuraminidase Inhibitors. *Carbohydr. Res.* **2019**, *477*, 32–38.

(32) Visini, R.; Jin, X.; Bergmann, M.; Michaud, G.; Pertici, F.; Fu, O.; Pukin, A.; Branson, T. R.; Thies-Weesie, D. M. E.; Kemmink, J.; Gillon, E.; Imberty, A.; Stocker, A.; Darbre, T.; Pieters, R. J.; Reymond, J.-L. Structural Insight into Multivalent Galactoside Binding to Pseudomonas Aeruginosa Lectin LecA. *ACS Chem. Biol.* **2015**, *10*, 2455–2462.

(33) Yang, Y.; Liu, H.-P.; Yu, Q.; Yang, M.-B.; Wang, D.-M.; Jia, T.-W.; He, H.-J.; He, Y.; Xiao, H.-X.; Iyer, S. S.; Fan, Z.-C.; Meng, X.; Yu, P. Multivalent S-Sialoside Protein Conjugates Block Influenza Hemagglutinin and Neuraminidase. *Carbohydr. Res.* **2016**, *435*, 68–75.

(34) Griffith, B. R.; Krepel, C.; Fu, X.; Blanchard, S.; Ahmed, A.; Edmiston, C. E.; Thorson, J. S. Model for Antibiotic Optimization via Neoglycosylation: Synthesis of Liponeglycopeptides Active against VRE. *J. Am. Chem. Soc.* **2007**, *129*, 8150–8155.

(35) Spicer, C. D.; Davis, B. G. Rewriting the Bacterial Glycocalyx via Suzuki–Miyaura Cross-Coupling. *Chem. Commun.* **2013**, *49*, 2747–2749.

(36) Ohlsson, J.; Nilsson, U. J. A Galabiose-Based Two-Dimensional Scaffold for the Synthesis of Inhibitors Targeting P_k- and P-Antigen Binding Proteins. *Tetrahedron Lett.* **2003**, *44*, 2785–2787.

(37) Li, J.; Kendig, C. E.; Nesterov, E. E. Chemosensory Performance of Molecularly Imprinted Fluorescent Conjugated Polymer Materials. *J. Am. Chem. Soc.* **2007**, *129*, 15911–15918.

(38) Kuang, J.; Xie, X.; Ma, S. A General Approach to Terminal Allenols. *Synthesis* **2013**, *45*, 592–595.

(39) Paoloni, F. P. V.; Kelling, S.; Huang, J.; Elliott, S. R. Sensor Array Composed of “Clicked” Individual Microcantilever Chips. *Adv. Funct. Mater.* **2011**, *21*, 372–379.

(40) Hawkins, P. C. D.; Skillman, A. G.; Warren, G. L.; Ellingson, B. A.; Stahl, M. T. Conformer Generation with OMEGA: Algorithm and Validation Using High Quality Structures from the Protein Databank and Cambridge Structural Database. *J. Chem. Inf. Model.* **2010**, *50*, 572–584.

(41) McGann, M. FRED and HYBRID Docking Performance on Standardized Datasets. *J. Comput.-Aided Mol. Des.* **2012**, *26*, 897–906.

(42) Du, W.; Dai, M.; Li, Z.; Boons, G.-J.; Peeters, B.; van Kuppeveld, F. J. M.; de Vries, E.; de Haan, C. A. M. Substrate Binding by the Second Sialic Acid-Binding Site of Influenza A Virus N1 Neuraminidase Contributes to Enzymatic Activity. *J. Virol.* **2018**, *92*, e01243–e01248.

(43) Dai, M.; Guo, H.; Dortmans, J. C. F. M.; Dekkers, J.; Nordholm, J.; Daniels, R.; van Kuppeveld, F. J. M.; de Vries, E.; de Haan, C. A. M. Identification of Residues That Affect Oligomerization and/or Enzymatic Activity of Influenza Virus H5N1 Neuraminidase Proteins. *J. Virol.* **2016**, *90*, 9457–9470.

(44) Maines, T. R.; Jayaraman, A.; Belser, J. A.; Wadford, D. A.; Pappas, C.; Zeng, H.; Gustin, K. M.; Pearce, M. B.; Viswanathan, K.; Shriver, Z. H.; Raman, R.; Cox, N. J.; Sasisekharan, R.; Katz, J. M.; Tumpey, T. M. Transmission and Pathogenesis of Swine-Origin 2009 A(H1N1) Influenza Viruses in Ferrets and Mice. *Science* **2009**, *325*, 484–487.

(45) Du, W.; Wolfert, M. A.; Peeters, B.; van Kuppeveld, F. J. M.; Boons, G. J.; de Vries, E.; de Haan, C. A. M. Mutation of the Second Sialic Acid-Binding Site of Influenza A Virus Neuraminidase Drives Compensatory Mutations in Hemagglutinin. *PLoS Pathog.* **2020**, *16*, No. e1008816.

Recommended by ACS

Structural and Functional Analysis of Anti-Influenza Activity of 4-, 7-, 8- and 9-Deoxygenated 2,3-Difluoro-N-acetylneuraminic Acid Derivatives

Jennifer L. McKimm-Breschkin, Victor A. Streltsov, et al.

FEBRUARY 03, 2018
JOURNAL OF MEDICINAL CHEMISTRY

READ 

Human Neuraminidases: Structures and Stereoselective Inhibitors

Erika Bourguet, Manuela Maria Fraçzek, et al.

FEBRUARY 16, 2022
JOURNAL OF MEDICINAL CHEMISTRY

READ 

N-Substituted Valiolamine Derivatives as Potent Inhibitors of Endoplasmic Reticulum α -Glucosidases I and II with Antiviral Activity

Sharanbasappa S. Karade, Roy A. Mariuzza, et al.

DECEMBER 06, 2021
JOURNAL OF MEDICINAL CHEMISTRY

READ 

Efficient Blocking of Enterovirus 71 Infection by Heparan Sulfate Analogues Acting as Decoy Receptors

Daniel F. Earley, Mark von Itzstein, et al.

JULY 15, 2019
ACS INFECTIOUS DISEASES

READ 

Get More Suggestions >